The Rate of Type Ia Supernovae at z~0.2 from SDSS-I Overlapping Fields

In the course of the Sloan Digital Sky Survey (SDSS-I), a large fraction of the surveyed area was observed more than once due to field tiling overlap, usually at different epochs. We utilize some of these data to perform a supernova (SN) survey at a mean redshift of z=0.2. Our archival search, in ~ 5% of the SDSS-I overlap area, produces 29 SN candidates clearly associated with host galaxies. Using the Bayesian photometric classification algorithm of Poznanski et al., and correcting for classification bias, we find 17 of the 29 candidates are likely Type Ia SNe. Accounting for the detection efficiency of the survey and for host extinction, this implies a Type Ia SN rate of R=14.0+(2.5,1.4}-(2.5,1.1}+/-2.5 10^-14 h(70)^2 yr^-1 L_sun^-1, where the errors are Poisson error, systematic detection efficiency error, and systematic classification error, respectively. The volumetric rate is R=1.89+(0.42,0.18)-(0.34,0.15)+/-0.42 10^-5 yr^-1 h(70)^3 Mpc^-3. Our measurement is consistent with other rate measurements at low redshift. An order of magnitude increase in the number of SNe is possible by analyzing the full SDSS-I database.Comment: 11 pages, 7 figures, Accepted by MNRA

Differentially Evolved Genes of Salmonella Pathogenicity Islands: Insights into the Mechanism of Host Specificity in Salmonella

BACKGROUND: The species Salmonella enterica (S. enterica) includes many serovars that cause disease in avian and mammalian hosts. These serovars differ greatly in their host range and their degree of host adaptation. The host specificity of S. enterica serovars appears to be a complex phenomenon governed by multiple factors acting at different stages of the infection process, which makes identification of the cause/s of host specificity solely by experimental methods difficult. METHODOLOGY/PRINCIPAL FINDINGS: In this study, we have employed a molecular evolution and phylogenetics based approach to identify genes that might play important roles in conferring host specificity to different serovars of S. enterica. These genes are 'differentially evolved' in different S. enterica serovars. This list of 'differentially evolved' genes includes genes that encode translocon proteins (SipD, SseC and SseD) of both Salmonella pathogenicity islands 1 and 2 encoded type three secretion systems, sptP, which encodes an effector protein that inhibits the mitogen-activated protein kinase pathway of the host cell, and genes which encode effector proteins (SseF and SifA) that are important in placing the Salmonella-containing vacuole in a juxtanuclear position. CONCLUSIONS/SIGNIFICANCE: Analysis of known functions of these 'differentially evolved genes' indicates that the products of these genes directly interact with the host cell and manipulate its functions and thereby confer host specificity, at least in part, to different serovars of S. enterica that are considered in this study

Sloan Digital Sky Survey IV: Mapping the Milky Way, Nearby Galaxies, and the Distant Universe

We describe the Sloan Digital Sky Survey IV (SDSS-IV), a project encompassing three major spectroscopic programs. The Apache Point Observatory Galactic Evolution Experiment 2 (APOGEE-2) is observing hundreds of thousands of Milky Way stars at high resolution and high signal-to-noise ratios in the near-infrared. The Mapping Nearby Galaxies at Apache Point Observatory (MaNGA) survey is obtaining spatially resolved spectroscopy for thousands of nearby galaxies (median $z\sim 0.03$). The extended Baryon Oscillation Spectroscopic Survey (eBOSS) is mapping the galaxy, quasar, and neutral gas distributions between $z\sim 0.6$ and 3.5 to constrain cosmology using baryon acoustic oscillations, redshift space distortions, and the shape of the power spectrum. Within eBOSS, we are conducting two major subprograms: the SPectroscopic IDentification of eROSITA Sources (SPIDERS), investigating X-ray AGNs and galaxies in X-ray clusters, and the Time Domain Spectroscopic Survey (TDSS), obtaining spectra of variable sources. All programs use the 2.5 m Sloan Foundation Telescope at the Apache Point Observatory; observations there began in Summer 2014. APOGEE-2 also operates a second near-infrared spectrograph at the 2.5 m du Pont Telescope at Las Campanas Observatory, with observations beginning in early 2017. Observations at both facilities are scheduled to continue through 2020. In keeping with previous SDSS policy, SDSS-IV provides regularly scheduled public data releases; the first one, Data Release 13, was made available in 2016 July

The mutable nature of particle-core excitations with spin in the one-valence-proton nucleus ¹³³Sb

The γ-ray decay of excited states of the one-valence-proton nucleus ¹³³Sb has been studied using cold-neutron induced fission of ²³⁵U and ²⁴¹Pu targets, during the EXILL campaign at the ILL reactor in Grenoble. By using a highly efficient HPGe array, coincidences between γ-rays prompt with the fission event and those delayed up to several tens of microseconds were investigated, allowing to observe, for the first time, high-spin excited states above the 16.6 μs isomer. Lifetimes analysis, performed by fast-timing techniques with LaBr₃(Ce) scintillators, revealed a difference of almost two orders of magnitude in B(M1) strength for transitions between positive-parity medium-spin yrast states. The data are interpreted by a newly developed microscopic model which takes into account couplings between core excitations (both collective and non-collective) of the doubly magic nucleus ¹³²Sn and the valence proton, using the Skyrme effective interaction in a consistent way. The results point to a fast change in the nature of particle-core excitations with increasing spin

Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study.

We aimed to accurately estimate the frequency of a hexanucleotide repeat expansion in C9orf72 that has been associated with a large proportion of cases of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD)

Photonic glass ceramics based on SnO2 nanocrystals: advances and perspectives

Trabajo presentado al XVII Optical Components and Materials, celewbrado en San Francisco, California (USA) del 1 al 6 de febrero de 2020.SnO2-based glass-ceramics activated by rare earth ions have been extensively investigated because of the need to develop reliable fabrication protocols and clarify some interesting optical, structural, and spectroscopic features of the system. There is one important weakness in glass photonics when the rare earth ions are employed as luminescent sources. This is the low absorption cross section of the electronic states of the rare earth ions. A sensitizer is therefore requested. In the last years, we demonstrated that SiO2-SnO2 glass ceramics, presenting a strong absorption cross section in the UV range due to the SnO2 nanocrystal, are effective rare earth ions sensitizers. Another interesting property of the SiO2-SnO2 system is its photorefractivity. The high photorefractivity of sol-gel-derived SnO2-SiO2 glass-ceramic waveguides has been demonstrated in several papers published by our consortium. It has been shown that the UV irradiation induces refractive index change allowing the direct writing of both channel waveguides and Bragg gratings. The results presented in this communication not only demonstrate the viability and outstanding properties of the SiO2- SnO2 glass-ceramics for photonic applications but also put the basis for the fabrication of solid state and integrated lasers. The next steps of the research are the fabrication of the channels and mirrors exploiting the photorefractivity as well as to draw glass ceramic fiber, checking the lasing action and corresponding functional characteristics. Finally, it is worth noting that the dynamic of the energy transfer from the nanocrystals to the rare earth ions is still an exciting open question.This research is performed in the framework of the projects ERANet-LAC “RECOLA” (2017-2019), Centro Fermi MiFo (2017–2020) and NaWaGui (ANR-18-MRS1-0014). WB and MF acknowledge the support of CNR-STM - Short Term Mobility program 2019-2020.Peer reviewe

Pegylated Interferon Alfa-2b Plus Ribavirin in the Retreatment of Interferon-Ribavirin Nonresponder Patients

Background & Aims: Inadequate data are available about retreatment of nonresponders to interferon (IFN) and ribavirin. Thus, this study evaluated the efficacy and tolerability of a 48-week therapy with pegylated IFN-α-2b plus high-dose ribavirin in patients who have failed to respond to the combination. Treatment up to 48 weeks also in patients who have failed to clear hepatitis C virus (HCV) RNA by week 24 was also evaluated. Methods: One hundred forty-one patients who previously did not respond to IFN and ribavirin, 86% with genotype 1 or 4 infection, 52% with high viral load (>800.000 IU/mL), 22% with cirrhosis, were retreated with pegylated IFN-α-2b 1.5 μg/kg per week and ribavirin 1000-1200 mg/day for 48 weeks and followed up for 24 weeks. Results: By intent-to-treat analysis, 20% of patients achieved a sustained virologic response (SVR). SVR of genotype 1 patients was 19%. Independent predictors of SVR were low γ-glutamyltransferase levels (OR, 22.9; 95% CI: 6.6-79.6) and low viral load (OR, 3.8; 95% CI: 1.1-12.6). Twelve (23%) out of 51 patients who were HCV RNA positive after 24 weeks of therapy achieved a late virologic response (after week 24) and 5 (10%) of them, all with genotype 1, achieved an SVR. Genotype was not associated with response (P = .2) or with early response (P = .3). Conclusions: Retreatment with pegylated IFN-α-2b and ribavirin of multiexperienced and "difficult to treat" nonresponder patients produced a very promising SVR. Accurate selection of patients, such as those with low viral load and low γ-glutamyltransferase levels, and prolongation of therapy beyond 24 weeks also in HCV RNA-positive patients may further increase the rate of SVR. © 2006 American Gastroenterological Association Institute

Pegylated Interferon Alfa-2b Plus Ribavirin in the Retreatment of Interferon-Ribavirin Nonresponder Patients

Background & Aims: Inadequate data are available about retreatment of nonresponders to interferon (IFN) and ribavirin. Thus, this study evaluated the efficacy and tolerability of a 48-week therapy with pegylated IFN-α-2b plus high-dose ribavirin in patients who have failed to respond to the combination. Treatment up to 48 weeks also in patients who have failed to clear hepatitis C virus (HCV) RNA by week 24 was also evaluated. Methods: One hundred forty-one patients who previously did not respond to IFN and ribavirin, 86% with genotype 1 or 4 infection, 52% with high viral load (>800.000 IU/mL), 22% with cirrhosis, were retreated with pegylated IFN-α-2b 1.5 μg/kg per week and ribavirin 1000-1200 mg/day for 48 weeks and followed up for 24 weeks. Results: By intent-to-treat analysis, 20% of patients achieved a sustained virologic response (SVR). SVR of genotype 1 patients was 19%. Independent predictors of SVR were low γ-glutamyltransferase levels (OR, 22.9; 95% CI: 6.6-79.6) and low viral load (OR, 3.8; 95% CI: 1.1-12.6). Twelve (23%) out of 51 patients who were HCV RNA positive after 24 weeks of therapy achieved a late virologic response (after week 24) and 5 (10%) of them, all with genotype 1, achieved an SVR. Genotype was not associated with response (P = .2) or with early response (P = .3). Conclusions: Retreatment with pegylated IFN-α-2b and ribavirin of multiexperienced and "difficult to treat" nonresponder patients produced a very promising SVR. Accurate selection of patients, such as those with low viral load and low γ-glutamyltransferase levels, and prolongation of therapy beyond 24 weeks also in HCV RNA-positive patients may further increase the rate of SVR. © 2006 American Gastroenterological Association Institute